Probi AB (publ) (STO:PROB)

Market Cap	3.97B
Revenue (ttm)	630.39M
Net Income (ttm)	10.88M
Shares Out	11.39M
EPS (ttm)	0.96
PE Ratio	364.31
Forward PE	138.23
Dividend	1.30 (0.37%)
Ex-Dividend Date	May 8, 2024

Volume	2,929
Average Volume	1,378
Open	347.00
Previous Close	348.00
Day's Range	347.00 - 348.00
52-Week Range	197.00 - 352.00
Beta	0.44
RSI	53.03
Earnings Date	Jan 28, 2025

About Accolade

Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children’s, women’s, and senior health, as well as iron absorption. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beve...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 160
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROB

Financial Performance

In 2023, Probi AB's revenue was 627.69 million, an increase of 1.52% compared to the previous year's 618.29 million. Earnings were 16.82 million, a decrease of -58.60%.